Sotelo A I, Bartke A, Kopchick J J, Knapp J R, Turyn D
Instituto de Química y Fisicoquímica Biológicas (UBA-CONICET), Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina.
J Endocrinol. 1998 Jul;158(1):53-9. doi: 10.1677/joe.0.1580053.
We have examined the regulation of hepatic growth hormone receptors (GH-R) and serum GH binding proteins (GHBP) in transgenic mice expressing an antagonist of bovine growth hormone (bGH), G119K-bGH, and consequently exhibiting a growth suppressed dwarf phenotype. Specific GHBP could be measured in transgenic dwarf mouse serum only by immunological methods (RIA), because these mice have a very high concentration of mutated bGH in circulation (> 1 microgram/ml) and, therefore, almost all GHBP is bound to G119K-bGH and cannot be quantitated in binding assays. The concentrations of GHBP were 0.6 +/- 0.4 nM and 1.7 +/- 0.4 nM for normal and dwarf mice respectively. The concentrations of free GHBP in normal mice and in transgenic mice expressing wild-type GH can be calculated using chromatographic techniques as the dissociation constant (Kd) and the ratio of bound 125I-GH to free 125I-GH in the serum ([GHBP]free = B/F.Kd). In agreement with the assumption that GHBP reflects GH-R status, liver uptake of injected labeled bGH was greatly reduced in transgenic dwarfs in comparison with normal mice or with transgenic mice expressing wild-type bGH (liver/blood ratio of 0.48 +/- 0.21, 2.7 +/- 0.2, and 1.3 +/- 0.3 respectively) indicating that the high concentration of the mutated bGH (G119K-bGH) prevents labeled bGH uptake, as was expected from the dwarf phenotype. 125I-bGH taken up by the liver of transgenic dwarf mice was found in a smaller molecular species than in normal mice, compatible with the presence of 1:1 [(GH-R):GH] complexes instead of the 2:1 [(GH-R)2:GH] or 2:2 [(GHBP)2:(GH)2] complexes found in normal mice. The concentration of IGF-I, the principal mediator of GH activity, in the G119K-bGH transgenic mice was correlated with the concentration of free GHBP. This allowed us to use free GHBP concentration as a marker of the effects of the active endogenous hormone (mGH) on liver receptors in the presence of different concentrations of the antagonist of GH. The levels of GHBP in serum, as well as the concentration of GH-R in liver microsomes from mice expressing the bGH antagonist, are up-regulated by the high concentration of G119K-bGH (85%), but significantly less so than that which could be expected for the same concentration of native GH (220-275%). This up-regulation suggests that the G119K-bGH antagonist is internalized and induces synthesis of the receptor and of the binding protein.
我们研究了表达牛生长激素(bGH)拮抗剂G119K-bGH、因而表现出生长受抑制的侏儒表型的转基因小鼠肝脏生长激素受体(GH-R)和血清生长激素结合蛋白(GHBP)的调节情况。由于这些小鼠循环中突变型bGH浓度非常高(>1微克/毫升),因此几乎所有的GHBP都与G119K-bGH结合,无法在结合试验中进行定量,所以只能通过免疫方法(放射免疫分析,RIA)来检测转基因侏儒小鼠血清中的特异性GHBP。正常小鼠和侏儒小鼠的GHBP浓度分别为0.6±0.4纳摩尔/升和1.7±0.4纳摩尔/升。正常小鼠和表达野生型GH的转基因小鼠血清中游离GHBP的浓度可以使用色谱技术,根据解离常数(Kd)以及血清中结合的125I-GH与游离的125I-GH的比例来计算([GHBP]游离 = B/F.Kd)。与GHBP反映GH-R状态的假设一致,与正常小鼠或表达野生型bGH的转基因小鼠相比,转基因侏儒小鼠肝脏对注射的标记bGH的摄取显著降低(肝脏/血液比值分别为0.48±0.21、2.7±0.2和1.3±0.3),这表明高浓度的突变型bGH(G119K-bGH)阻止了标记bGH的摄取,正如从侏儒表型所预期的那样。发现转基因侏儒小鼠肝脏摄取的125I-bGH存在的分子种类比正常小鼠中的小,这与存在1:1 [(GH-R):GH]复合物而非正常小鼠中发现的2:1 [(GH-R)2:GH]或2:2 [(GHBP)2:(GH)2]复合物相符。生长激素活性的主要介导因子胰岛素样生长因子-I(IGF-I)在G119K-bGH转基因小鼠中的浓度与游离GHBP的浓度相关。这使我们能够在存在不同浓度生长激素拮抗剂的情况下,将游离GHBP浓度用作活性内源激素(mGH)对肝脏受体作用的标志物。表达bGH拮抗剂的小鼠血清中GHBP的水平以及肝脏微粒体中GH-R的浓度,都因高浓度的G119K-bGH而上调(85%),但上调程度明显低于相同浓度天然GH预期的上调程度(220 - 275%)。这种上调表明G119K-bGH拮抗剂被内化,并诱导受体和结合蛋白的合成。